{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T11:43:48Z","timestamp":1778327028865,"version":"3.51.4"},"reference-count":14,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2021-0138_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Oxaliplatin immune-induced syndrome (OIIS) was recently recognized as an uncommon complication of oxaliplatin therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2021-0138_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We report an exceptionally OIIS after pressurized intraperitoneal aerosol chemotherapy (PIPAC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2021-0138_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our patient developed a severe OIIS probably related to the intraperitoneal administration of oxaliplatin. Specific tests were performed and detected high-titer antibodies to oxaliplatin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2021-0138_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The OIIS is a rare. Physicians had to be aware of that clinical situation because it could be reversible, even in case of peritoneal advanced disease, and ICU treatment is justified.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2021-0138","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T09:52:56Z","timestamp":1643449976000},"page":"35-38","source":"Crossref","is-referenced-by-count":5,"title":["A severe oxaliplatin immune-induced syndrome after oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy (PIPAC)"],"prefix":"10.1515","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0270-5090","authenticated-orcid":false,"given":"Anne-Cecile","family":"Ezanno","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal and Endocrine Surgery , B\u00e9gin Military Hospital , St Mand\u00e9 , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brice","family":"Malgras","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal and Endocrine Surgery , B\u00e9gin Military Hospital , St Mand\u00e9 , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Aoun","sequence":"additional","affiliation":[{"name":"46th Medical Unit, 5th Armed Forces Medical Center , Strasbourg , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amaury","family":"Delarge","sequence":"additional","affiliation":[{"name":"Department of Acute Care Unit , B\u00e9gin Military Hospital , St Mand\u00e9 , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Doreille","sequence":"additional","affiliation":[{"name":"Department of Nephrology , Tenon Hospital , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Pocard","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal and Cancerology , Piti\u00e9 Salpetri\u00e8re Hospital , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"key":"2025120909240605386_j_pp-2021-0138_ref_001","doi-asserted-by":"crossref","unstructured":"Bencardino, K, Mauri, G, Amatu, A, Tosi, F, Bonazzina, E, Palmeri, L, et al.. Oxaliplatin immune-induced syndrome occurs with cumulative administration and rechallenge: single institution series and systematic review study. Clin Colorectal Cancer 2016;15:213\u201321. https:\/\/doi.org\/10.1016\/j.clcc.2016.02.001.","DOI":"10.1016\/j.clcc.2016.02.001"},{"key":"2025120909240605386_j_pp-2021-0138_ref_002","doi-asserted-by":"crossref","unstructured":"George, JN, Nester, CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014;371:1847\u20138. https:\/\/doi.org\/10.1056\/NEJMra1312353.","DOI":"10.1056\/NEJMc1410951"},{"key":"2025120909240605386_j_pp-2021-0138_ref_003","doi-asserted-by":"crossref","unstructured":"Al-Nouri, ZL, Reese, JA, Terrell, DR, Vesely, SK, George, JN. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood 2015;125:616\u20138. https:\/\/doi.org\/10.1182\/blood-2014-11-611335.","DOI":"10.1182\/blood-2014-11-611335"},{"key":"2025120909240605386_j_pp-2021-0138_ref_004","doi-asserted-by":"crossref","unstructured":"Dumont, F, Senellart, H, Pein, F, Campion, L, Glehen, O, Goere, D, et al.. Phase I\/II study of oxaliplatin dose escalation via a laparoscopic approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable peritoneal metastases of digestive cancers (stomach, small bowel and colorectal): rationale and design. Pleura Peritoneum 2018;3:20180120. https:\/\/doi.org\/10.1515\/pp-2018-0120.","DOI":"10.1515\/pp-2018-0120"},{"key":"2025120909240605386_j_pp-2021-0138_ref_005","doi-asserted-by":"crossref","unstructured":"de Gramont, A, Figer, A, Seymour, M, Homerin, M, Hmissi, A, Cassidy, J, et al.. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J\u00a0Clin Oncol Off J Am Soc Clin Oncol 2000;18:2938\u201347. https:\/\/doi.org\/10.1200\/jco.2000.18.16.2938.","DOI":"10.1200\/JCO.2000.18.16.2938"},{"key":"2025120909240605386_j_pp-2021-0138_ref_006","doi-asserted-by":"crossref","unstructured":"Alyami, M, H\u00fcbner, M, Grass, F, Bakrin, N, Villeneuve, L, Laplace, N, et al.. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol 2019;20:e368\u201377. https:\/\/doi.org\/10.1016\/s1470-2045(19)30318-3.","DOI":"10.1016\/S1470-2045(19)30318-3"},{"key":"2025120909240605386_j_pp-2021-0138_ref_007","doi-asserted-by":"crossref","unstructured":"Stack, A, Khanal, R, Denlinger, CS. Oxaliplatin-induced immune thrombocytopenia: a case report and literature review. Clin Colorectal Cancer 2020;20:1\u20134.","DOI":"10.1016\/j.clcc.2020.07.007"},{"key":"2025120909240605386_j_pp-2021-0138_ref_008","doi-asserted-by":"crossref","unstructured":"van den Bemt, PMLA, Meyboom, RHB, Egberts, ACG. Drug-induced immune thrombocytopenia. Drug Saf 2004;27:1243\u201352. https:\/\/doi.org\/10.2165\/00002018-200427150-00007.","DOI":"10.2165\/00002018-200427150-00007"},{"key":"2025120909240605386_j_pp-2021-0138_ref_009","doi-asserted-by":"crossref","unstructured":"Curtis, SA, Curtis, BR, Lee, AI, Hendrickson, JE, Lacy, J, Podoltsev, NA. A patient with oxaliplatin immune-induced syndrome (OIIS) who also developed leucovorin and palonosetron-associated thrombocytopenia. Hematol Amst Neth 2018;23:429\u201332. https:\/\/doi.org\/10.1080\/10245332.2017.1419600.","DOI":"10.1080\/10245332.2017.1419600"},{"key":"2025120909240605386_j_pp-2021-0138_ref_010","doi-asserted-by":"crossref","unstructured":"Ito, I, Ito, Y, Mizuno, M, Suzuki, Y, Yasuda, K, Ozaki, T, et al.. A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin. Clin Exp Nephrol 2012;16:490\u20134. https:\/\/doi.org\/10.1007\/s10157-012-0620-8.","DOI":"10.1007\/s10157-012-0620-8"},{"key":"2025120909240605386_j_pp-2021-0138_ref_011","doi-asserted-by":"crossref","unstructured":"Yamada, S, Yazawa, M, Yamamoto, M, Koitabashi, K, Ichikawa, D, Koike, J, et al.. A case of biopsy-proven oxaliplatin-induced acute tubulointerstitial nephritis with thrombocytopenia and anemia. CEN Case Rep 2019;8:188\u201393. https:\/\/doi.org\/10.1007\/s13730-019-00390-8.","DOI":"10.1007\/s13730-019-00390-8"},{"key":"2025120909240605386_j_pp-2021-0138_ref_015","doi-asserted-by":"crossref","unstructured":"Vyskocil, J, Tucek, S, Kiss, I, Fedorova, L, Nevrlka, J, Zdrazilova-Dubska, L. Type II hypersensitivity reactions after oxaliplatin rechallenge can be life threatening. Int Immunopharmacol 2019;74:105728. https:\/\/doi.org\/10.1016\/j.intimp.2019.105728.","DOI":"10.1016\/j.intimp.2019.105728"},{"key":"2025120909240605386_j_pp-2021-0138_ref_012","doi-asserted-by":"crossref","unstructured":"Norton, A, Roberts, I. Management of Evans syndrome. Br J Haematol 2006;132:125\u201337. https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05809.x.","DOI":"10.1111\/j.1365-2141.2005.05809.x"},{"key":"2025120909240605386_j_pp-2021-0138_ref_013","doi-asserted-by":"crossref","unstructured":"Leger, RM, Garratty, G. Antibodies to oxaliplatin, a chemotherapeutic, are found in plasma of healthy blood donors. Transfusion (Paris) 2011;51:1740\u20134. https:\/\/doi.org\/10.1111\/j.1537-2995.2010.03040.x.","DOI":"10.1111\/j.1537-2995.2010.03040.x"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2021-0138\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2021-0138\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:01:48Z","timestamp":1765278108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2021-0138\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,3,9]]},"published-print":{"date-parts":[[2022,3,9]]}},"alternative-id":["10.1515\/pp-2021-0138"],"URL":"https:\/\/doi.org\/10.1515\/pp-2021-0138","relation":{},"ISSN":["2364-768X"],"issn-type":[{"value":"2364-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,31]]}}}